agilon health inc

Price has decisively broken below the key support cluster and is trading under declining EMAs, confirming a medium-term bearish structure. Short-term timing is neutral as price consolidates around current support, so execution should be deferred to trim into rallies toward resistance zones.

• ↑Q2 revenue grew 7% YoY to $1.5B; medical margin turned positive at $197M vs –$53M prior.
• ↑Adjusted EBITDA of $70M in Q2 vs a –$83M loss last year.
• ↓Negative profitability factor and negative earnings yield raise valuation concerns.